Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | PPARD | Q03181 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 8/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756348 | 1.00 | PPARG (0.64) | PPARGPPARDHPGDCNR1PTPN1 | |
| SCHEMBL5757849 | 0.90 | HPGD (0.57) | PPARGPPARDHPGDCNR1PTPN1 | |
| SCHEMBL5757847 | 0.90 | HPGD (0.57) | PPARGPPARDHPGDCNR1PTPN1 | |
| SCHEMBL5758203 | 0.90 | HPGD (0.72) | PPARGPPARDHPGDPTPN1POLB | |
| SCHEMBL5758206 | 0.90 | HPGD (0.72) | PPARGPPARDHPGDPTPN1POLB | |
| SCHEMBL5755920 | 0.89 | HPGD (0.71) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5755915 | 0.89 | HPGD (0.71) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5757163 | 0.87 | PIM1 (0.55) | PPARGPPARDHPGDPOLBMMP3 | |
| SCHEMBL5757161 | 0.87 | PIM1 (0.55) | PPARGPPARDHPGDPOLBMMP3 | |
| SCHEMBL5758972 | 0.82 | HPGD (0.75) | PPARGPPARDHPGDPTPN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | claimed |
| EP-1179343-B1 | REMEDIES FOR DIABETES COMPRISING 2-(N-CYANOIMINO)THIAZOLIDINE-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2004-08-18 | — | — | EP | claimed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | claimed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | claimed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | claimed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1179343-B1 | REMEDIES FOR DIABETES COMPRISING 2-(N-CYANOIMINO)THIAZOLIDINE-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | APOL1, NR1H2, CYP8B1 | PPARG 1375/4885PPARD 1158/4885HPGD 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.